



Rapid report

Activation by methylene blue of large  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels

James D. Stockand<sup>a,b</sup>, Steven C. Sansom<sup>a,b,\*</sup>

<sup>a</sup> Department of Medicine, Division of Renal Diseases and Hypertension, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA

<sup>b</sup> Department of Integrative Biology, University of Texas Medical School at Houston, Houston, TX, USA

Received 12 August 1996; accepted 3 September 1996

**Abstract**

Using the patch-clamp method, we found that methylene blue (MB), a free radical inhibitor of guanylyl cyclase, activated large,  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels ( $\text{BK}_{\text{Ca}}$ ) in either cell attached or excised, inside-out patches of human mesangial cells in culture. Since  $\text{BK}_{\text{Ca}}$  are important feedback regulators of contraction of smooth muscle and mesangial cells, these results indicate that MB may be an important opener of  $\text{BK}_{\text{Ca}}$  channels and a regulator of vascular volume and resistance.

**Keywords:** Methylene blue; Potassium ion channel,  $\text{Ca}^{2+}$ -activated ( $\text{BK}_{\text{Ca}}$ ); Guanylyl cyclase inhibitor; LY83583; Patch clamp

It has been documented in several studies that vasorelaxants, such as nitric oxide (NO) and atrial natriuretic peptide, attenuate contraction of smooth muscle [1–3] and mesangial cells [4,5], in part, by activating  $\text{BK}_{\text{Ca}}$  via a cGMP-dependent signal transduction pathway. In our laboratory, it was shown that the guanylyl cyclase inhibitor, LY83583, inhibited the activation of  $\text{BK}_{\text{Ca}}$  by nitroprusside, an NO donor [4]. However, methylene blue, a free radical inhibitor of guanylyl cyclase, failed to inhibit the activation of  $\text{BK}_{\text{Ca}}$  by nitroprusside [4]. We therefore determined if methylene blue directly activates  $\text{BK}_{\text{Ca}}$  in human mesangial cells. These results could partially explain the controversial finding of direct activation of  $\text{BK}_{\text{Ca}}$  by nitric oxide and the conflicting reports regarding the multiple effects of methylene blue on smooth muscle and mesangial cell tone [6–9]. Moreover,

because  $\text{BK}_{\text{Ca}}$  are important regulators of contraction of vascular smooth muscle and glomerular mesangial cells, an opener of these channels would be expected to influence blood pressure and volume and could thereby have clinical and therapeutic significance.

Mesangial cells were isolated from human kidneys and cultured using the following standard techniques [10]. Mesangial cells were plated in Waymouth's culture media (pH = 7.4), supplemented with 15 mM *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid (Hepes), 2.0 mM glutamine, 0.66 U/ml insulin, 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids, antibiotic solution (100 units/ml penicillin and 100  $\mu\text{g}/\text{ml}$  streptomycin) and 17% (v/v) newborn calf serum. Subpassages four through ten were used in all experiments. It was shown by Mene et al. [11] that this generation span of MC maintain a constant phenotype and typical smooth muscle-like spindle shape. Moreover, our laboratory has shown that these generations maintain the consistent transcription [12]

\* Corresponding author (at address a). Fax: +1 (713) 7941 197.

and expression of BK<sub>Ca</sub> responsive to cGMP-activated protein kinase [5,13].

Mesangial cells were prepared for single channel analysis using standard patch-clamp techniques previously described [13,14]. Pipette and bath solutions contained (in mM): 10 Hepes (pH = 7.4), 2 MgCl<sub>2</sub> and either 140 KCl or 135 NaCl plus 5 KCl. The free Ca<sup>2+</sup> concentration of the bath (initially 1.0 mM) was adjusted to lower concentrations by buffering with EGTA as described previously [15].

After obtaining gigaohm seals, current recordings were made with the electrode on the cell surface (cell attached) or after withdrawing the patched membrane (excised, inside-out). The unitary current (*i*; defined as zero for C) was determined as the mean of the best fit Gaussian distribution of the amplitude histograms. Channels were considered in an open state (S) when the current was  $>(n-1/2)i$  and  $<(n+1/2)i$ , where *n* is the number of current levels. The open state probability of a channel (*P*<sub>o</sub>) is defined as the time spent in S divided by the total time of the recording. In all cases,  $-V_p$  is the holding potential relative to the pipette.

All chemicals were purchased from Sigma (St. Louis), except LY83583, which was purchased from Calbiochem (La Jolla, CA). For paired data and multiple comparisons, the paired *t*-test and an analysis of variance plus the Student–Newman–Keuls test, respectively, were used to establish statistical differences ( $p \leq 0.05$ ).

Table 1

The effect of methylene blue (MB) and LY83583 on the activation of BK<sub>Ca</sub> by nitroprusside

Agents	<i>P</i> <sub>o</sub>
Control (13)	0.03 ± 0.01
Nitroprusside (6)	0.38 ± 0.07
Nitroprusside + LY83583 (4)	0.03 ± 0.01
Nitroprusside + MB (6)	0.46 ± 0.07

Values are open probability of BK<sub>Ca</sub> in cell attached patches bathed with 135 mM NaCl plus 5 mM KCl and 1 mM CaCl<sub>2</sub>.  $-V_p = 80$  mV, Nitroprusside = 0.1 mM, methylene blue = 0.1 mM, LY83583 = 1.0 μM.  $p \leq 0.05$  vs. control (ANOVA + SNK test).

Fig. 1 shows current tracings of BK<sub>Ca</sub> in cell attached patches. As shown in Fig. 1A, nitroprusside (0.1 mM) activated BK<sub>Ca</sub> from a *P*<sub>o</sub> of <0.05 to a peak of 0.57. Over the next two minutes BK<sub>Ca</sub> activity returned to baseline. As shown in Fig. 1B, addition of nitroprusside in the presence of methylene blue (0.1 mM) activated BK<sub>Ca</sub> to a sustained *P*<sub>o</sub> of 0.47. As shown in Fig. 1C, BK<sub>Ca</sub> were not activated by nitroprusside in the presence of LY83583 (1.0 μM).

A summary of the effects of methylene blue and LY83583 on the activation of BK<sub>Ca</sub> by nitroprusside is shown in Table 1. In cell attached patches, nitroprusside activated BK<sub>Ca</sub> significantly in the absence or presence of methylene blue. However, nitroprusside failed to activate BK<sub>Ca</sub> in the presence of LY83583.




Fig. 1. (A) Current tracings of BK<sub>Ca</sub> in cell attached patches ( $-V_p = 80$  mV) with 135 mM NaCl plus 5 mM KCl in the bath. Addition of nitroprusside (0.1 mM) to the bathing solution ([Ca] = 1.0 mM) caused an activation of BK<sub>Ca</sub> from a *P*<sub>o</sub> of <0.05 to a peak of 0.57; after 1 min BK<sub>Ca</sub> activity returned to baseline. (B) Nitroprusside was added, under the same conditions, except in the presence of methylene blue (0.1 mM). BK<sub>Ca</sub> were activated to a sustained *P*<sub>o</sub> = 0.47. (C) In the presence of LY83583 (1.0 μM), BK<sub>Ca</sub> were not activated by nitroprusside (*P*<sub>o</sub> < 0.05).




Fig. 2. (A) Tracings of  $BK_{Ca}$  in a representative excised, inside-out patch ( $-V_p = -40$  mV and  $[Ca^{2+}]_i = 1.0$   $\mu$ M) showing the effects of methylene blue. In the upper tracing,  $P_o$  increased from 0.08 to 0.22 upon addition of 10  $\mu$ M methylene blue. In the lower tracing, 0.1 mM methylene blue activated  $BK_{Ca}$  to 0.54. (B) Current tracings showing that LY83583 did not affect  $BK_{Ca}$  under the same conditions. Open probability was  $< 0.05$  before and after the addition of LY83583 (top tracing = 1.0  $\mu$ M, bottom tracing = 0.1 mM).

The representative current tracings (excised, inside-out) of Fig. 2A show that methylene blue activated  $BK_{Ca}$  directly in a dose-dependent manner. Upon addition of 10  $\mu$ M and 0.1 mM methylene blue,  $P_o$  increased from 0.08 to 0.22 and 0.54, respectively. In six paired, excised, inside-out experiments ( $-V_p = -40$  mV,  $[Ca^{2+}]_i = 1.0$   $\mu$ M) methylene blue significantly ( $p < 0.001$ ) activated  $BK_{Ca}$  from a  $P_o$  of  $0.09 \pm 0.02$  to  $0.45 \pm 0.05$ . In contrast, as shown by the representative current tracings of

Fig. 2B, LY83583 (0.1 mM and 1.0  $\mu$ M) did not affect  $BK_{Ca}$ . In four paired experiments, LY83583 did not activate  $BK_{Ca}$  ( $p = 0.64$ ). Thus, methylene blue, but not LY83583, activated  $BK_{Ca}$  directly from the intracellular side.

It was found that 0.1 mM methylene blue did not affect significantly ( $p = 0.18$ ) solution pH ( $7.37 \pm 0.01$  and  $7.38 \pm 0.01$ , respectively, before and after addition of methylene blue). Thus, the effects of methylene blue on  $BK_{Ca}$  cannot be attributed to changing solution pH.

As an inhibitor of guanylyl cyclase [16,17], methylene blue has been used in several studies to determine the role for cGMP in relaxation of smooth muscle cells [18–20].  $BK_{Ca}$  channels hyperpolarize the membrane and inhibit contraction of mesangial cells [4] and vascular smooth muscle [22] by reducing voltage-gated Ca entry. Although some studies show that methylene blue inhibits arterial relaxation by cGMP-stimulating relaxants [18–21], other studies show methylene blue either had no effect [7–9] or augmented NO-induced relaxation of vascular smooth muscle [6]. It is possible that these conflicting studies are due to simultaneous inhibition of guanylate cyclase and activation of  $BK_{Ca}$  channels.

The finding that methylene blue directly activates  $BK_{Ca}$  can partially explain the effects reported by Bolotina, who found that NO activated  $BK_{Ca}$  after addition of methylene blue [23]. Although Bolotina also found a direct activation by NO of  $BK_{Ca}$  in excised patches, it is likely that many intracellular compounds and enzymes, such as guanylyl cyclase and protein kinase G are present in the excised patch. A recent study in this laboratory provided evidence that cGMP-activated kinase was present with  $BK_{Ca}$  in excised patches [4]. The absence of direct  $BK_{Ca}$  activation by NO was also supported by the recent study by McCobb et al. who found no direct effect of nitroprusside on the gene product for *hsl*, a human  $BK_{Ca}$  of vascular smooth muscle expressed in *Xenopus* oocytes [24].

It is postulated that methylene blue inhibits soluble guanylyl cyclase by oxidation of its heme center [20]. However, because methylene blue is an electron acceptor, multiple actions, other than specifically inhibiting guanylyl cyclase, would be expected. Methylene blue causes the release of noradrenaline from adrenergic nerve endings [25], inhibits production of

prostacyclin in arteries [26], and inhibits release of NO from organic nitrates [27].

In conclusion, our results can explain some of the paradoxical and ambiguous effects of methylene blue on the response of vascular cells to relaxing agents. Based on these results, LY83583 would be a more suitable agent for determining the signaling pathways for relaxing agents. The notion that methylene blue can open BK<sub>Ca</sub> channels could have therapeutic consequences for regulating glomerular filtration rate or vascular smooth muscle tension.

The human glomerular mesangial cells were a generous gift from Hanna Abboud (U of TX-HSC, San Antonio). Steve Sansom was supported by American Diabetes Association award #89.

## References

- [1] Robertson, B.E., Schubert, R., Hescheler, J. and Nelson, M.T. (1993) *Am. J. Physiol. Cell Physiol.* 265, C299–C303.
- [2] Murray, J.A., Shibata, E.F., Buresh, T.L., Picken, H., O'Meara, B.W. and Conklin, J.L. (1995) *Am. J. Physiol. Gastrointest. Liver Physiol.* 269, G606–G612.
- [3] White, R.E., Lee, A.B., Shcherbatko, A.D., Lincoln, T.M., Schonbrun, A. and Armstrong, D.L. (1993) *Nature* 361, 263–266.
- [4] Stockand, J.D. and Sansom, S.C. (1996) *Am. J. Physiol. Cell Physiol.* 270, 1773–1779.
- [5] Sansom, S.C. and Stockand, J.D. (1996) *Clin. Exp. Pharm. Physiol.* 23, 76–82.
- [6] Gryglewski, R.J., Zembowicz, A., Salvemini, D., Taylor, G.W. and Vane, J.R. (1992) *Br. J. Pharmacol.* 106, 838–845.
- [7] Okamura, T., Inoue, M. and Toda, N. (1990) *Eur. J. Pharmacol.* 183, 1267–1268.
- [8] Kreye, V.A.W. (1995) *J. Cardiovasc. Pharmacol.* 6, 5646–5655.
- [9] Marshall, J.J., Wei, E.P. and Kontos, H.A. (1988) *Am. J. Physiol.* 255, H847–H854.
- [10] Jaffer, F., Saunders, C., Shultz, P., Throckmorton, D., Weinsell, E. and Abboud, H.E. (1989) *Am. J. Pathol.* 135, 261–269.
- [11] Mene, P., Simonson, M.S. and Dunn, M.J. (1989) *Physiol. Rev.* 69, 1347–1424.
- [12] Sansom, S.C., Lopreato, G., Stockand, J. and Atkinson, N. (1995) *JASN* 6, 350 (abstr.).
- [13] Stockand, J.D. and Sansom, S.C. (1994) *Am. J. Physiol. Cell Physiol.* 267, C1080–C1086.
- [14] Hamill, O.P., Marty, A., Neher, E., Sackmann, B. and Sigworth, F.J. (1981) *Pfluegers Arch.* 391, 85–100.
- [15] Fabiato, A. and Fabiato, F. (1979) *J. Physiol.* 75, 463–505.
- [16] Miki, N., Kawabe, Y. and Kuriyama, K. (1977) *Biochem. Biophys. Res. Commun.* 75, 851–856.
- [17] Murad, F., Mittal, C.K., Arnold, W.P., Katsuki, S. and Kimura, H. (1978) *Adv. Cycl. Nuc. Res.* 9, 145–158.
- [18] Gruetter, C.A., Gruetter, D.Y., Lyon, J.E., Kadowitz, P.J. and Ignarro, L.J. (1981) *J. Pharmacol. Exp. Ther.* 219, 181–186.
- [19] Gruetter, C.A., Kadowitz, P.J. and Ignarro, L.J. (1980) *Can. J. Physiol. Pharmacol.* 59, 150–156.
- [20] Martin, W., Villani, G.M., Jothianandan, D. and Furchgott, R.F. (1984) *J. Pharmacol. Exp. Ther.* 232, 708–716.
- [21] Marezin, N., Ryan, U.S. and Catravas, J.D. (1992) *J. Pharmacol. Exp. Ther.* 263, 170–179.
- [22] Nelson, M.T. and Quayle, J.M. (1995) *Am. J. Physiol.* 268, C799–C822.
- [23] Bolotina, V.M., Najibi, S., Palacino, J.J., Paganò, P.J. and Cohen, R.A. (1994) *Nature* 368, 850–853.
- [24] McCobb, D.P., Fowler, N.L., Featherstone, T., Lingle, C.J., Saito, M., Krause, J.E. and Salkoff, L. (1995) *Am. J. Physiol. Heart Circ. Physiol.* 269, H767–H777.
- [25] Matsuo, I., Sakurai, K., Ono, T. and Nakanishi, H. (1987) *Jpn. J. Pharmacol.* 44, 23–33.
- [26] Martin, W., Drazan, K.M. and Newby, A.C. (1989) *Br. J. Pharmacol.* 97, 51–56.
- [27] Feilisch, M. and Noack, E.A. (1987) *Eur. J. Pharmacol.* 139, 19–30.